Trial Profile

Iadademstat with Hypomethylating Agent in Patients with Myelodysplastic Syndrome

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 15 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Iadademstat (Primary)
Indications Myelodysplastic syndromes; Myeloid leukaemia; Myeloproliferative disorders
Focus Adverse reactions

Most Recent Events

12 May 2025 According to an Oryzon media release, trial is led by the Medical College of Wisconsin (MCW), has also continued to actively enroll patients during this quarter and completed the first cohort.
07 Feb 2025 Planned number of patients changed from 9 to 12.
07 Feb 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com